ClinicalTrials.gg
CompletedNCT00537940Updated Jan 22, 2021Results posted

Comparative Study Of Pregabalin And Gabapentin As Adjunctive Therapy In Subjects With Partial Seizures

A Phase 4 interventional study of Pregabalin and Gabapentin in Epilepsy, Partial Seizure Disorder and Epilepsies, Partial, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 8 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-01-22.

Primary conditionEpilepsies, PartialRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsies, Partial
Why
  1. The study's listed conditions name Epilepsies, Partial, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
4th of 18
482 · median 244
Started
2008
with 1 other
Phase 4
4 of 18
none open now
Registered
14th of 18
by date
Lead sponsor
10 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 4 in phase 4, and was the 14th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

To compare the efficacy of pregabalin and gabapentin, as adjunctive therapy in subjects with partial seizures.

03

Conditions studied

  • Epilepsy
  • Partial Seizure Disorder
  • Epilepsies, Partial
  • Complex Partial Seizure Disorder

Browse trials for

04

In context

Epilepsies, Partial Reclassified

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

This study's enrollment of 482 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.

Browse Epilepsies, Partial studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Compared within Epilepsies, Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects (male or female) must be > 18 years or ≤ 80 years of age, with a diagnosis of epilepsy with partial seizures, as defined in the International League Against Epilepsy (ILAE) classification of seizures; partial seizures may be simple or complex, with or without secondary tonic-clonic generalization.
  • Subjects must be have been diagnosed with epilepsy for at least 2 years, and must have been unresponsive to treatment with at least two but no more than five prior antiepileptic drugs (AEDs), and at the time of study enrollment are on stable dosages of 1 or 2 standard AEDs.
  • They must have had a 12 lead (ECG) without abnormal findings prior to randomization.
  • Subjects must have had magnetic resonance imaging or contrast enhance computed tomography scan of the brain that demonstrated no progressive structural central nervous system abnormality at the time of the diagnosis of epilepsy.
  • Women of must be established on an effective method of during the study. Women should also have a negative pregnancy test prior to study entry.
  • During the 6-week baseline period, subjects must have had a minimum of four partial seizures, with no 28 day period free of partial seizures with or without secondary generalization. A caregiver or witness must be with the subject for a sufficient duration to accurately chronicle the occurrence of seizures. These seizures must have been documented in the subject's diary.
  • Subjects with electroencephalograph (EEG) testing done within 2 years of randomization. EEG abnormalities should be consistent with a diagnosis of focal-onset epilepsy.
  • Signed and dated will be obtained from each subject (only include those able to consent) in accordance with the local regulatory and legal requirements.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures. Subjects who are willing, but need assistance for self administered questionnaires may be considered acceptable, but must first be discussed on a case-by-case basis with the Pfizer monitor prior to any to any screening tests or procedures for the study.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, breastfeeding, or intending to become pregnant during the course of the trial.
  • Subjects with other neurologic illness that could impair endpoint assessment, or patients with Lennox-Gastaut syndrome, absence seizures, status epilepticus within the 12 months prior to study entry, or with seizures due to an underlying medical illness or metabolic syndrome.
  • Subjects with liver disease or with a calculated of \<60mL/min.
  • Subjects with a history of lack of response, or poor tolerability to gabapentin or pregabalin.
  • Previous use of gabapentin or pregabalin within 2 weeks prior to screening or likelihood of engaging in these treatments during the study period.
  • Use of prohibited medications as listed in the protocol in the absence of appropriate phase or the likelihood of requiring treatment during the study period with drugs not permitted by the study protocol.
  • Participation in any other studies involving or marketed products, concomitantly or within 30 days prior to entry in the study.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.
  • Subjects who are not suitable to be treated with pregabalin or gabapentin according to the respective local labeling.
  • Subjects with a history of retinal abnormalities or treatment with retinotoxic agents.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
482 participants (actual)

Study arms

  • Active comparator
    A

    Drug: Pregabalin

  • Active comparator
    B

    Drug: Gabapentin

Interventions

  • 150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects

  • 300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects

07

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in 28-day Seizure Frequency at Week 21.

    The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure \[SGTC\]).

    Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

Secondary outcomes

  1. Percentage of Participants With 50% Reduction From Baseline in 28-day Seizure Rate at Week 21.

    Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline \<= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no).

    Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

  2. Percentage of Participants With 75% Reduction From Baseline in 28-day Seizure Rate at Week 21.

    Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline \<= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC).

    Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

  3. Percentage of Participants Without Seizures.

    Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.

    Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

  4. Change From Baseline in the 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Frequency at Week 21.

    Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline.

    Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

  5. Reduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21.

    SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate.

    Time frame: 6 weeks Baseline, 21 weeks through End of MP for 27 weeks

  6. Hospital Anxiety and Depression Scale (HADS) Score.

    HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline, Week 21

  7. Medical Outcomes Study Sleep Scale (MOS-SS) Score.

    Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score \[RS\] minus lowest possible score divided by possible RS range\*100); total score range:0-100; higher score=more intensity of attribute.

    Time frame: Baseline, Week 21

  8. Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score.

    MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.

    Time frame: Baseline, Week 21

08

Results

Posted Aug 8, 2014

Participant flow

Overall, 561 participants were screened and 482 participants participated in the study; 242 participants were randomized but one participant from the pregabalin group and one participant from the gabapentin group were not treated. Hence 241 participants were treated in each treatment group. Participants were randomized at 56 centers.

Participant flow — Overall Study
MilestonePregabalinGabapentin
Started241241
Completed titration phase213210
Completed maintenance phase187172
Entered opt blinded continuation phase140139
Completed5862
Not completed183179
Withdrew: Adverse event2019
Withdrew: Lack of efficacy816
Withdrew: Lost to follow-up2329
Withdrew: Withdrawal by subject11395
Withdrew: Protocol violation64
Withdrew: Pregnancy11
Withdrew: Study terminated by sponsor23
Withdrew: Other1012

Outcome measures

PrimaryPercent Change From Baseline in 28-day Seizure Frequency at Week 21.

The seizures were recorded by the participants, by a family member, by a caregiver, or by a legal guardian and documented in a daily seizure diary. Participant's 28-day seizure frequency of all partial seizure was assessed during double blind (TP + MP) phase compared with baseline. Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + secondary generalized tonic clonic seizure \[SGTC\]).

Time frame:
6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Reported as:
Median · percent change
Percent Change From Baseline in 28-day Seizure Frequency at Week 21.
percent changePregabalinGabapentin
Percent Change From Baseline in 28-day Seizure Frequency at Week 21.-58.65 (-100.0 to 180.0)-57.43 (-100.0 to 392.4)
Statistical analysis
  • Pregabalin vs Gabapentin · Ranked ANCOVA · p = 0.8708 · Median difference (final values): 0.0 · 95% CI -6.0 to 7.0
SecondaryPercentage of Participants With 50% Reduction From Baseline in 28-day Seizure Rate at Week 21.

Participants who had at least 50% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 50% responders. If percent change from baseline \<= -50 then responder rate = 1 (yes) otherwise responder rate = 0 (no).

Time frame:
6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With 50% Reduction From Baseline in 28-day Seizure Rate at Week 21.
Percentage of participantsPregabalinGabapentin
All Partial Seizure (n=238, 240)56.3 (50.0 to 62.6)58.3 (52.1 to 64.6)
Simple Partial (n=87, 88)55.2 (44.7 to 65.6)53.4 (43.0 to 63.8)
Complex Partial (n=161, 158)56.5 (48.9 to 64.2)55.1 (47.3 to 62.8)
SGTC (n=112, 114)50.9 (41.6 to 60.2)60.5 (51.6 to 69.5)
Statistical analysis
  • Pregabalin vs Gabapentin · Regression, Logistic · p = 0.662 · Odds ratio (or): 0.920 · 95% CI 0.635 to 1.335
SecondaryPercentage of Participants With 75% Reduction From Baseline in 28-day Seizure Rate at Week 21.

Participants who had at least 75% reduction in seizure frequency from Baseline to double-blind treatment (TP + MP) were considered as 75% responders. If percent change from baseline \<= -75 then 75% responder rate = 1 (yes) otherwise responder rate = 0 (no). Total partial seizure is defined as the total number of (simple partial seizure + complex partial seizure + SGTC).

Time frame:
6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With 75% Reduction From Baseline in 28-day Seizure Rate at Week 21.
Percentage of participantsPregabalinGabapentin
All Partial Seizure (n=238, 240)33.6 (27.6 to 39.6)34.2 (28.2 to 40.2)
Simple Partial (n=87, 88)36.8 (26.7 to 46.9)33.0 (23.1 to 42.8)
Complex Partial (n=161, 158)37.3 (29.8 to 44.7)36.1 (28.6 to 43.6)
SGTC (n=112, 114)38.4 (29.4 to 47.4)43.9 (34.8 to 53.0)
Statistical analysis
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.9232 (All partial seizure: p-value was calculated from the 2-sided Fisher's exact test.)
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.6361 (Simple Partial: p-value was calculated from the 2-sided Fisher's exact test.)
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.9075 (Complex partial: p-value was calculated from the 2-sided Fisher's exact test.)
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.4203 (SGTC seizure: p-value was calculated from the 2-sided Fisher's exact test.)
SecondaryPercentage of Participants Without Seizures.

Seizure free for 28 days was defined as participants who have not experienced any seizure (simple partial, complex partial and SGTC) for at least 28 consecutive days from their last seizure until the end of the MP. Same participant could be seizure free for a specific type of seizure but not necessarily for the other types of seizure.

Time frame:
6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Without Seizures.
percentage of participantsPregabalinGabapentin
All Partial Seizure (n=189, 182)30.7 (24.1 to 37.3)34.1 (27.2 to 41.0)
Simple Partial (n=74, 66)29.7 (19.3 to 40.1)36.4 (24.8 to 48.0)
Complex Partial (n=126, 123)37.3 (28.9 to 45.8)40.7 (32.0 to 49.3)
SGTC (n=95, 91)46.3 (36.3 to 56.3)42.9 (32.7 to 53.0)
Statistical analysis
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.5069 (All partial seizure: p-value was calculated from the 2-sided Fisher's exact test.)
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.4721 (Simple partial seizure: p-value was calculated from the 2-sided Fisher's exact test.)
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.6054 (Complex partial seizure: p-value was calculated from the 2-sided Fisher's exact test.)
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.6603 (SGTC seizure: p-value was calculated from the 2-sided Fisher's exact test.)
SecondaryChange From Baseline in the 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Frequency at Week 21.

Change in SGTC = (Proportion of SGTC/All Partial Seizure rate during at the double-blind phase) - (Proportion of SGTC/All Partial Seizure rate at Baseline). Negative values indicate reduction from baseline.

Time frame:
6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Reported as:
Mean · percentage of all partial seizure/28days
Change From Baseline in the 28-day Secondarily Generalized Tonic-clonic (SGTC) Seizure Frequency at Week 21.
percentage of all partial seizure/28daysPregabalinGabapentin
Baseline (n=114, 114)56.53 ± 40.85659.60 ± 40.571
Change from Baseline at Double Blind (n=104, 98)1.59 ± 28.164-2.17 ± 26.024
SecondaryReduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21.

SGTC Responder is defined as a participant who shows reduction from Baseline to double-blind phase in proportion of 28-Day SGTC Seizure Rate to 28-Day All Partial Seizure Rate.

Time frame:
6 weeks Baseline, 21 weeks through End of MP for 27 weeks
Reported as:
Number · percentage of responders
Reduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21.
percentage of respondersPregabalinGabapentin
Reduction in Proportion of the 28-day SGTC Seizure Rate Over the Total Partial Seizure Rate at Week 21.30.8 (21.9 to 39.6)39.8 (30.1 to 49.5)
Statistical analysis
  • Pregabalin vs Gabapentin · Fisher Exact · p = 0.1881 (p-value is calculated using Fisher Exact Test.)
SecondaryHospital Anxiety and Depression Scale (HADS) Score.

HADS: participant rated questionnaire with 2 subscales. Hospital Anxiety and Depression Scale - anxiety (HADS-A) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); Hospital Anxiety and Depression Scale - depression (HADS-D) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline, Week 21
Reported as:
Least squares mean · Units on a scale
Hospital Anxiety and Depression Scale (HADS) Score.
Units on a scalePregabalinGabapentin
Baseline HADS-A (n=238, 240)7.82 ± 0.317.60 ± 0.31
HADS- A Change at Week 21/ET (n=212, 210)-0.92 ± 0.26-0.83 ± 0.27
Baseline HADS-D (n=238, 240)5.94 ± 0.295.65 ± 0.29
HADS-D Change at Week 21/ET (n=212, 210)-0.59 ± 0.24-0.42 ± 0.24
Statistical analysis
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.5643 · Ls mean difference (final values): 0.22 · 95% CI -0.53 to 0.97
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.7712 · Ls mean difference (final values): 0.09 · 95% CI -0.73 to 0.54
  • Pregabalin vs Gabapentin · Ranked ANCOVA · p = 0.4236 · Ls mean difference (final values): 0.28 · 95% CI -0.41 to 0.97
  • Pregabalin vs Gabapentin · Ranked ANCOVA · p = 0.5492 · Ls mean difference (final values): -0.17 · 95% CI -0.75 to 0.40
SecondaryMedical Outcomes Study Sleep Scale (MOS-SS) Score.

Participant-rated 12-item questionnaire to assess constructs of sleep over past week; 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence (range:0-100); sleep quantity (range:0-24), optimal sleep (yes/no), and 9 item index measures of sleep disturbance provide composite scores: sleep problem summary, overall sleep problem. Except adequacy, optimal sleep and quantity, higher scores=more impairment. Scores transformed (actual raw score \[RS\] minus lowest possible score divided by possible RS range\*100); total score range:0-100; higher score=more intensity of attribute.

Time frame:
Baseline, Week 21
Reported as:
Least squares mean · Units on a scale
Medical Outcomes Study Sleep Scale (MOS-SS) Score.
Units on a scalePregabalinGabapentin
Baseline: Sleep Disturbance (n=238, 240)29.68 ± 1.7026.43 ± 1.70
Baseline: Snoring (n=238, 240)29.28 ± 2.3128.09 ± 2.31
Baseline: Awaken Short of Breath (n=238, 240)23.64 ± 2.0719.61 ± 2.07
Baseline: Quantity of Sleep (n=238, 240)7.56 ± 0.117.59 ± 0.11
Baseline: Adequacy of Sleep (n=238, 240)61.30 ± 2.0163.67 ± 2.01
Baseline: Somnolence (n=238, 240)32.29 ± 1.5629.31 ± 1.56
Baseline: Sleep Problem Index (9) (n=238, 240)31.60 ± 1.3228.15 ± 1.32
Week 21: Sleep Disturbance (n=212, 210)24.99 ± 1.3725.31 ± 1.39
Week 21: Snoring (n=212, 210)28.07 ± 1.8926.12 ± 1.90
Week 21: Awaken Short of Breath (n=212, 210)16.26 ± 1.7318.20 ± 1.74
Week 21: Quantity of Sleep (n=212, 210)8.79 ± 0.178.77 ± 0.17
Week 21: Adequacy of Sleep (n=212, 210)63.87 ± 1.6864.53 ± 1.69
Week 21: Somnolence (n=212, 210)32.04 ± 1.3629.98 ± 1.37
Week 21: Sleep Problem Index (9) (n=212, 210)27.88 ± 1.0427.54 ± 1.05
Statistical analysis
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.1160 · Ls mean difference (final values): 3.25 · 95% CI -0.81 to 7.31
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.8490 · Ls mean difference (final values): -0.32 · 95% CI -3.62 to 2.98
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.6728 · Ls mean difference (final values): 1.19 · 95% CI -4.34 to 6.73
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.3954 · Ls mean difference (final values): 1.96 · 95% CI -2.56 to 6.47
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.1106 · Ls mean difference (final values): 4.03 · 95% CI -0.92 to 8.98
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.3603 · Ls mean difference (final values): -1.93 · 95% CI -6.09 to 2.22
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.8312 · Ls mean difference (final values): -0.03 · 95% CI -0.30 to 0.24
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.9101 · Ls mean difference (final values): 0.02 · 95% CI -0.38 to 0.42
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.3346 · Ls mean difference (final values): -2.37 · 95% CI -7.19 to 2.45
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.7491 · Ls mean difference (final values): -0.66 · 95% CI -4.69 to 3.37
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.1162 · Ls mean difference (final values): 2.98 · 95% CI -0.74 to 6.71
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.2163 · Ls mean difference (final values): 2.06 · 95% CI -1.21 to 5.32
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.0321 · Ls mean difference (final values): 3.45 · 95% CI 0.30 to 6.61
  • Pregabalin vs Gabapentin · ANCOVA · p = 0.7889 · Ls mean difference (final values): 0.34 · 95% CI -2.17 to 2.85
SecondaryPercentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score.

MOS-SS: participant-rated 12 item questionnaire to assess constructs of sleep over past week. It included 7 subscales: sleep disturbance, snoring, awakened short of breath, sleep adequacy, somnolence, sleep quantity and optimal sleep. Participants responded whether their sleep was optimal or not by choosing yes or no. Percentage of participants with optimal sleep are reported.

Time frame:
Baseline, Week 21
Reported as:
Number · percentage of participants
Percentage of Participants With Optimal Sleep Assessed Using Medical Outcomes Study-Sleep Scale (MOS-SS) Score.
percentage of participantsPregabalinGabapentin
Baseline (n=238, 240)49.258.8
Week 21 (n=212, 210)51.458.6
Statistical analysis
  • Pregabalin vs Gabapentin · Regression, Logistic · p = 0.0252 · Odds ratio (or): 0.653 · 95% CI 0.449 to 0.948
  • Pregabalin vs Gabapentin · Regression, Logistic · p = 0.3459 · Odds ratio (or): 0.811 · 95% CI 0.524 to 1.254

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—13/241 (5.4%)77/241 (32%)
Gabapentin—14/241 (5.8%)77/241 (32%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventPregabalinGabapentin
ConvulsionNervous system disorders3/2410/241
PneumoniaInfections and infestations2/2410/241
EpilepsyNervous system disorders0/2412/241
Status epilepticusNervous system disorders0/2412/241
Suicidal ideationPsychiatric disorders2/2410/241
Atrial fibrillationCardiac disorders1/2410/241
Pericardial effusionCardiac disorders1/2410/241
VertigoEar and labyrinth disorders0/2411/241
DiplopiaEye disorders0/2411/241
Rectal haemorrhageGastrointestinal disorders1/2410/241
Most frequent other events
Most frequent other events
EventPregabalinGabapentin
SomnolenceNervous system disorders35/24134/241
HeadacheNervous system disorders21/24125/241
Weight increasedInvestigations23/24115/241
DizzinessNervous system disorders22/24121/241
Dry mouthGastrointestinal disorders12/2418/241

Baseline characteristics

Age, Continuous
Age, Continuous(years)PregabalinGabapentinTotal
Mean34.9 ± 13.035.3 ± 12.935.1 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinGabapentinTotal
Female114111225
Male127130257
09

Study locations

8 sites
  • Hospital Clinica Biblica
    San Jose, Costa Rica
  • Instituto de Neurociencias
    San Salvador, 01503, El Salvador
  • Clinica de Especialidades Neurologicas
    San Salvador, El Salvador
  • Private Office
    Guatemala Ciudad, 01014, Guatemala
  • Private Office
    Guatemala, Guatemala
  • Clinica Anglo Americana
    Lima, 27, Peru
  • Torre de Consultorios Clinica Anglo Americana
    Lima, L-27, Peru
  • Hospital Nacional Guillermo Almenara Irigoyen - Essalud
    Lima, L13, Peru
10

References and documents

Publications

  • French J, Glue P, Friedman D, Almas M, Yardi N, Knapp L, Pitman V, Posner HB. Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology. 2016 Sep 20;87(12):1242-9. doi: 10.1212/WNL.0000000000003118. Epub 2016 Aug 12. PubMed 27521437 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2007
First posted
Oct 2, 2007
Start
Feb 2008
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Aug 8, 2014
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00537940
Responsible party
Sponsor
First posted
Oct 2, 2007
Start date
Feb 2008
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Aug 8, 2014
Last update
Jan 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Gabapentin

Start the discussion